A Phase 1 Study of KHN707 Tablets in Healthy Participants

Phase 1 Not yet recruiting 38 enrolled Chengdu Kanghong Pharmaceutical Co., Ltd.

RandomizedSequentialDouble-blindTreatment

Summary

This is a single-center, randomized, double-blind, placebo-controlled study . The objective is to evaluate the safety , tolerability and PK profile of KHN707 tablets in Chinese healthy participants.

Timeline

Start: 2026-05
Primary completion: 2026-10
Completion: 2026-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	KHN707	Unknown	—	Oral

Indications

No indication recorded.